▶주메뉴 바로가기
▶본문 바로가기
Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ HealthCare and Hanmi Pharmaceutical all announced in the first half of 2019 that they would begin or exp...
South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada. The regulatory body Health Canada has approved the data from nonclinical and clinical trials, and announced that Herzuma’s safety and effectiveness are compara...
South Korea’s Supreme Court has approved a grace period for Samsung BioLogics to defer the implementation of penalties imposed by the financial authorities by up to 30 days, the biopharma firm said in a regulatory filing on Sept. 10. As a result, sanctions on Samsung’s biopharma arm by Korea’...
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on Aug. 28. “On Aug. 20, we answered the European Medicines Agency’s questions related to Remsima SC,...
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1 clinical trial will be conducted among 90 patients who suffer non-Hodgkin’s lymphoma, a type of c...
The Korea Exchange, South Korea’s stock market operator, on Aug. 26 announced its decision to delist troubled Kolon Group ’s US gene therapy-developing unit Kolon TissueGene . In late March, a component of Kolon TissueGene’s gene therapy drug Invossa -- labeled as “a gene-containing chondr...
Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the Korean company plans to mainly conduct clinical trials to prove the safety of its biosimilars to loc...
South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its partnership with US companies and apply for clinical trials after establishing the new unit. Accord...
Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on open innovation for discovering new drug candidates and technologies,” the company said in a stat...
SillaJen shares bottomed out on Aug. 2 on news that the global phase 3 clinical trials of its signature liver cancer treatment Pexa-Vec are likely to be suspended. The biotech firm trading on South Korea’s tech-heavy bourse Kosdaq, took a 30 percent loss. As a result, the market cap fell to 2.2 ...
Celltrion announced on Aug. 1 that it had started a phase 3 clinical trial of its new drug Remsima SC in the US. Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of Johnson & Johnson’s autoimmune disease therapy Remicade. According to the company, the new pen-type...
South Korean pharmaceutical firm Samsung Bioepis said on July 24 it has won approval from the US Food and Drug Administration to sell one of its biosimilars in the United States. Hadlima, referencing AbbVie’s blockbuster autoimmune treatment Humira, can be also used for treatment of diseases t...
The value of stocks owned by both former and current entertainment agency owners in South Korea dropped nearly 30 percent compared to last year, data showed on July 21, as the industry is struggling to cope with a slew of scandals as well as trade tensions between Korea and Japan, a key market. Ac...
Three-dimensional printing of human organs is not some far-fetched fiction. Active research of the relevant technologies has gained pace around the globe, especially here in South Korea, where the academia, industry and government are paying keen attention to the convergence of medicine, mechanical...
South Korean biopharma firms Chong Kun Dang and Dong-A ST expect to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Japanese partner firms. The erythropoietin drug Nesp, for which the patent expires in Japan this year...
Korean builders nervous about possible setbacks in Middle East
HD Hyundai chair receives honorary doctorate from HUFS
SC Bank Korea offers special interest rate for new members
Hyundai-Kia marks 40 years of partnerships with over 100 suppliers: report
Samsung expected to introduce new Exynos processor in next Galaxy series
Woori, KB ink QR code payment partnership with Cambodia